Why wouldn't you take Omega 3's?
Posted: Thu Aug 18, 2005 9:59 am
New evidence supporting the use of Omega 3's for MS:
Prostaglandins Leukot Essent Fatty Acids. 2005 Aug 12;
Low fat dietary intervention with omega-3 fatty acid supplementation in multiple sclerosis patients.
Weinstock-Guttman B, Baier M, Park Y, Feichter J, Lee-Kwen P, Gallagher E, Venkatraman J, Meksawan K, Deinehert S, Pendergast D, Awad AB, Ramanathan M, Munschauer F, Rudick R.
Baird Multiple Sclerosis Center for MS Treatment and Research, Jacobs Neurological Institute, State University of New York, 100 High Street, Buffalo General Hospital-E2, Buffalo, NY 14203, USA.
Objectives: To determine whether a low fat diet supplemented with omega-3 positively affects quality of life (QOL) in relapsing-remitting MS (RRMS) patients. In this 1-year long double-blind, randomized trial, patients were randomized to two dietary interventions: the "Fish Oil" (FO) group received a low fat diet (15% fat) with omega-3 FOs and the "Olive Oil" (OO) group received the AHA Step I diet (fat 30%) with OO supplements.
The primary outcome measure was the Physical Components Summary Scale (PCS) of the Short Health Status Questionnaire (SF-36). Additional measures using MS specific QOL questionnaires, neurological status and relapse rate were obtained.
Results: 31 RRMS patients were enrolled, with mean follow up over 11+/-SD 2.9 months. Clinical benefits favoring the FO group were observed on PCS/SF-36 (P=0.050) and MHI (P=0.050) at 6 months. Reduced fatigue was seen on the OO diet at 6 months (P=0.035). The relapse rate decreased in both groups relative to the rates during the 1 year preceding the study: mean change in relapse rate in the FO group: -0.79+/-SD 1.12 relapses/year (P=0.021) vs. -0.69+/-SD 1.11 (P=0.044) in the OO group.
This study suggests that a low fat diet supplemented with omega-3 PUFA can have moderate benefits in RRMS patients on concurrent disease modifying therapies.
<shortened url>
Prostaglandins Leukot Essent Fatty Acids. 2005 Aug 12;
Low fat dietary intervention with omega-3 fatty acid supplementation in multiple sclerosis patients.
Weinstock-Guttman B, Baier M, Park Y, Feichter J, Lee-Kwen P, Gallagher E, Venkatraman J, Meksawan K, Deinehert S, Pendergast D, Awad AB, Ramanathan M, Munschauer F, Rudick R.
Baird Multiple Sclerosis Center for MS Treatment and Research, Jacobs Neurological Institute, State University of New York, 100 High Street, Buffalo General Hospital-E2, Buffalo, NY 14203, USA.
Objectives: To determine whether a low fat diet supplemented with omega-3 positively affects quality of life (QOL) in relapsing-remitting MS (RRMS) patients. In this 1-year long double-blind, randomized trial, patients were randomized to two dietary interventions: the "Fish Oil" (FO) group received a low fat diet (15% fat) with omega-3 FOs and the "Olive Oil" (OO) group received the AHA Step I diet (fat 30%) with OO supplements.
The primary outcome measure was the Physical Components Summary Scale (PCS) of the Short Health Status Questionnaire (SF-36). Additional measures using MS specific QOL questionnaires, neurological status and relapse rate were obtained.
Results: 31 RRMS patients were enrolled, with mean follow up over 11+/-SD 2.9 months. Clinical benefits favoring the FO group were observed on PCS/SF-36 (P=0.050) and MHI (P=0.050) at 6 months. Reduced fatigue was seen on the OO diet at 6 months (P=0.035). The relapse rate decreased in both groups relative to the rates during the 1 year preceding the study: mean change in relapse rate in the FO group: -0.79+/-SD 1.12 relapses/year (P=0.021) vs. -0.69+/-SD 1.11 (P=0.044) in the OO group.
This study suggests that a low fat diet supplemented with omega-3 PUFA can have moderate benefits in RRMS patients on concurrent disease modifying therapies.
<shortened url>